Shares of Urogen Pharma (NASDAQ:URGN) have earned a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.

Analysts have set a 1 year consensus price objective of $31.33 for the company and are forecasting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Urogen Pharma an industry rank of 106 out of 265 based on the ratings given to its competitors.

URGN has been the topic of a number of recent analyst reports. Oppenheimer Holdings, Inc. set a $32.00 price objective on Urogen Pharma and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research upgraded Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC lifted their price target on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, October 9th.

Shares of Urogen Pharma (NASDAQ:URGN) traded down 0.29% on Monday, reaching $27.20. The company’s stock had a trading volume of 9,654 shares. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $33.77. The firm’s 50-day moving average price is $29.80 and its 200-day moving average price is $21.41. The stock’s market cap is $353.84 million.

Hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. purchased a new position in shares of Urogen Pharma in the second quarter worth $195,000. Shikiar Asset Management Inc. purchased a new position in shares of Urogen Pharma in the third quarter worth $665,000. LLBH Private Wealth Management LLC purchased a new position in shares of Urogen Pharma in the second quarter worth $695,000. Spark Investment Management LLC purchased a new position in shares of Urogen Pharma in the second quarter worth $856,000. Finally, Menora Mivtachim Holdings LTD. purchased a new position in shares of Urogen Pharma in the second quarter worth $2,331,000. Hedge funds and other institutional investors own 36.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/analysts-expect-urogen-pharma-urgn-to-announce-0-05-eps.html.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.